Neurovascular Embolization Devices Global Market Report 2024

The neurovascular embolization devices market size has grown strongly in recent years. It will grow from $1.15 billion in 2023 to $1.23 billion in 2024 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to the rising geriatric population, the increased prevalence of neurovascular disorders, improved healthcare infrastructure, the demand for minimally invasive procedures, and increased healthcare expenditure.

The neurovascular embolization devices market size is expected to see strong growth in the next few years. It will grow to $1.6 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The anticipated growth during the forecast period can be credited to the broadening utilization in emerging markets, the focus on patient-centered care, heightened awareness regarding neurovascular disorders, progressions in imaging technologies, and augmented investments in research and development. Key trends in the projected period encompass personalized treatment strategies, the incorporation of artificial intelligence into treatment planning, the introduction of next-generation embolic materials, a transition towards outpatient and ambulatory procedures, and the innovation of advanced embolization techniques.

The increasing incidence of hemorrhages is anticipated to drive the neurovascular embolization devices market forward. Hemorrhages represent abnormal and uncontrollable bleeding occurring either internally within the body or externally through breaks in the skin or mucous membranes. Factors contributing to the prevalence of hemorrhages include aging populations, heightened occurrences of hypertension, and expanded usage of anticoagulant medications. Neurovascular embolization devices play a crucial role in managing hemorrhagic strokes by blocking abnormal blood vessels, thereby reducing bleeding and averting further brain damage. For example, recent research conducted by King’s College London indicates an expected 59.4% increase in cases and deaths from intracerebral hemorrhage (a specific type of hemorrhage) among individuals aged 70 to 95 across the UK by 2050. Consequently, the mounting prevalence of hemorrhages propels the growth of the neurovascular embolization devices market.

Major companies in the neurovascular embolization devices sector are concentrating on the development of technologically advanced products, such as shield technology, to address brain aneurysms and enhance their competitive position in the market. Shield Technology denotes an advanced attribute aimed at augmenting the effectiveness and safety of these devices while also contributing to their overall durability and longevity. For example, in June 2022, Medtronic PLC, an Ireland-based healthcare technology company, introduced the Pipeline Vantage with Shield Technology, a fourth-generation flow diverter in India. This device incorporates enhanced design features to enhance usability and reliability during endovascular procedures. By fostering cell growth in the blood vessel's inner lining, the device provides a scaffold that aids in the minimally invasive treatment of aneurysms, reduces the risk of rupture, and enhances patient outcomes.

In May 2023, Stryker Corporation, a US-based medical technology company, completed the acquisition of Cerus Endovascular Ltd for $530 million. This strategic move by Stryker was aimed at strengthening its expertise in offering innovative medical devices tailored for treating intracranial aneurysms, including products such as the contour neurovascular system and the neqstent coil-assisted flow diverter. Cerus Endovascular Ltd, headquartered in Ireland, specializes in the development of cutting-edge neurovascular embolization devices designed specifically for the treatment of intracranial aneurysms.

Major companies operating in the neurovascular embolization devices market are Johnson & Johnson, Abbott Laboratories, Medtronic plc, Heraeus Holding, Stryker Corporation, Boston Scientific Corporation, Kaneka Corporation, Terumo Corporation, B Braun Melsungen AG, Cook Medical LLC, Integer Holdings Corporation, Merit Medical Systems Inc, Penumbra Inc, Asahi Intecc Co Ltd, MicroVention Inc, Balt USA LLC, Imperative Care Inc, InNeuroCo Inc, Acandis GmbH & Co KG, Rapid Medical Ltd, Emboline Inc, InspireMD Inc, QXMedical LLC, Vesalio LLC, EmbolX Inc.

North America was the largest region in the neurovascular embolization devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurovascular embolization devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurovascular embolization devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Neurovascular embolization devices are medical tools utilized to address irregular blood vessels in the brain or central nervous system by obstructing or altering blood flow. They play a crucial role in neuro-interventional treatments aimed at addressing conditions such as aneurysms, arteriovenous malformations (AVMs), and arteriovenous fistulas (AVFs) that could lead to bleeding or other adverse outcomes.

The primary products within the category of neurovascular embolization devices comprise embolization coils, liquid embolic systems, flow diversion stents, aneurysm clips, and other related items. Embolization coils, constructed from materials such as platinum or stainless steel, are flexible devices employed to block blood flow within vessels. They are utilized in diverse treatments such as ischemic and hemorrhagic stroke solutions and are indicated for conditions such as brain aneurysms and arteriovenous malformations. These devices are utilized by various end-users including hospitals, ambulatory surgical centers, and others.

The neurovascular embolization devices market research report is one of a series of new reports that provides neurovascular embolization devices market statistics, including the neurovascular embolization devices industry global market size, regional shares, competitors with neurovascular embolization devices market share, detailed neurovascular embolization devices market segments, market trends, and opportunities, and any further data you may need to thrive in the neurovascular embolization devices industry. These neurovascular embolization devices market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurovascular embolization devices market consists of sales of particle embolic, detachable balloons, vascular plugs, and embolization microspheres. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.